Protein FLJ23867: A Potential Drug Target and Biomarker (G200058)

Target Name: Uncharacterized protein FLJ23867

NCBI ID: G200058

Uncharacterized protein FLJ23867

Other Name(s): FLJ23867

Protein FLJ23867: A Potential Drug Target and Biomarker

Abstract:
FLJ23867 is a unique and highly conserved protein that has been identified as a potential drug target and biomarker. Its structure, localization, and function have not been fully characterized, but its potential implications as a drug target and biomarker make it an important topic of study.

Introduction:
Proteins are the building blocks of life and play a crucial role in various cellular processes. Many proteins have been identified as potential drug targets due to their involvement in various cellular processes and their ability to interact with small molecules. FLJ23867 is one of these proteins that has gained significant attention due to its unique structure and localization.

Structure and Localization:
FLJ23867 is a protein that has 21 amino acid residues and a calculated molecular weight of 21 kDa. It is highly conserved, with a calculated conserved domain length of 11.5%, which suggests that it has important functions in various cellular processes. FLJ23867 is located in the cytoplasm and has been observed to localize to the endoplasmic reticulum (ER) and the trans-endoplasmic reticulum (TER), which are responsible for the delivery of proteins to different cellular compartments.

Function:
FLJ23867 is involved in various cellular processes, including cell signaling, DNA replication, and protein transport. It has been shown to play a role in regulating cell signaling pathways, such as the TGF-β pathway, which is involved in cell growth, differentiation, and survival. Additionally, FLJ23867 has been shown to be involved in regulating DNA replication, which is crucial for the maintenance of genetic information and the development of new organisms.

Potential Drug Target:
FLJ23867's unique structure and localization make it an attractive target for small molecules. Many drugs that are currently in use target proteins that are similar to FLJ23867, such as inhibitors of the TGF-β pathway. These drugs work by inhibiting the activity of the protein, which can lead to the inhibition of cell signaling pathways and ultimately lead to the inhibition of cellular processes.

Potential Biomarker:
FLJ23867 can also be used as a biomarker for various diseases, such as cancer. Its unique structure and localization make it an attractive target for cancer therapies that target the endoplasmic reticulum. Many cancer therapies work by delivering drugs to the endoplasmic reticulum, which can then be targeted to the cancer cells and inhibit their growth and proliferation.

Conclusion:
FLJ23867 is a unique and highly conserved protein that has the potential to be a drug target and biomarker. Its structure and localization make it an attractive target for small molecules, and its involvement in various cellular processes makes it an important topic of study. Further research is needed to fully understand the functions of FLJ23867 and its potential as a drug target and biomarker.

Protein Name: Uncharacterized Protein FLJ23867

The "Uncharacterized protein FLJ23867 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Uncharacterized protein FLJ23867 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets